trending Market Intelligence /marketintelligence/en/news-insights/trending/wo6jbkinhsruf559smlwjq2 content esgSubNav
In This List

Cytori Therapeutics regains Nasdaq compliance

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cytori Therapeutics regains Nasdaq compliance

Cytori Therapeutics Inc. said June 11 that it regained compliance with Nasdaq stock market's minimum bid price rule.

Related listing qualification matters have now been closed.

In May, the company implemented a 1-for-10 reverse stock split to regain compliance with the exchange's bid price listing requirement.

San Diego-based Cytori Therapeutics develops cellular therapeutics for specific diseases and medical conditions.